Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (\<100 cigarette, cigar or pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15 years) or have known EGFR activating mutation; or patients with HER 2 amplification or mutation.
Checked against the public recordLast updated Jan 8, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Pfizer
- Interventions being studied
- Drug: Dacomitinib (PF-00299804); Drug: Dacomitinib (PF-00299804)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Advanced adenocarcinoma of lung, measurable disease * Non-smoker, or former light (less than 10 pack years and stopped at least 15 years); OR * patients with known EGFR activating mutation regardless of smoking status * ECOG(Eastern Cooperative Oncology Group) 0-1. Cohort B (select sites only): patients with HER2 amplified or HER2 mutation-positive NSCLC; may have had prior therapy Exclusion Criteria: * Active brain metastases * Prior systemic therapy for advanced disease in Cohort A only. Cohort B can have had any number of prior lines of systemic therapy. * known EGFR wild type NSCLC
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of California, IrvineOrange, California
- Chao Family Comprehensive Cancer Center UC Irvine Medical CenterOrange, California
- Bay Area Cancer Research Group, LLCPleasant Hill, California
- Pacific Cancer CareSalinas, California
- San Francisco General HospitalSan Francisco, California
- University of Colorado Clinical Trials Office (CTO)Aurora, Colorado
- University of Colorado HospitalAurora, Colorado
- Florida Cancer SpecialistsFort Myers, Florida
- National Institutes of Health National Cancer InstituteBethesda, Maryland
- Massachusetts General HospitalBoston, Massachusetts
- Brigham & Women's HospitalBoston, Massachusetts
- Dana-Farber Cancer InstituteBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 8, 2019. Always confirm current availability with the study team.